April 30, 2019
May 6, 2019
Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors. In addition to its inhibition of tumor osteoclasis, it also produces certain killing of tumor cells. effect. Foreign studies have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain inhibitory effect on distant metastasis. We hope that it can reduce tumor recurrence and lung metastasis through this study.
|Experimental: experimental group
Drug: Zoledronic Acid
- Patients with osteosarcoma who were diagnosed with initial pathology and pathology
were excluded from lung metastasis or other metastatic lesions by CT and total body
emission-computed tomography, and patients with standard chemotherapy were evaluated.
- Pulmonary metastasis, pregnancy or lactation, renal insufficiency (creatinine
clearance <70 ml/min/1.73 m2), liver dysfunction, obvious oral disease, and unsuitable for bisphosphonate treatment after evaluation, have been found. With diseases that still require hormone therapy, abnormal blood system, heart disease
Contact: Xiaobo Yan, Dr. +8613588153306 firstname.lastname@example.org
2nd Affiliated Hospital of Zhejiang University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Principal Investigator: zhaoming Ye, Prof. 2nd Affiliated Hospital Of Zhejiang University